Cambrex Announces $120 Million Investment to Boost U.S. API Manufacturing Capacity Cambrex has declared a significant investment of $120 million aimed at expanding its manufacturing capabilities in the U.S., ensuring a robust drug supply chain.

Cambrex Announces $120 Million Investment to Boost U.S. API Manufacturing Capacity #USA #Cambrex #API_Manufacturing #Drug_Supply #Charles_City,_Iowa

Cambrex’s Bold $120 Million Investment to Enhance U.S. API Production for Drug Supply Stability Cambrex is investing $120 million to boost its API manufacturing capabilities in the U.S., enhancing drug supply stability amidst rising demand.

Cambrex’s Bold $120 Million Investment to Enhance U.S. API Production for Drug Supply Stability #USA #Cambrex #API_Manufacturing #Drug_Supply #Charles_City

Cambrex Announces $120 Million Investment in U.S. API Manufacturing to Ensure Drug Supply Resilience Cambrex has revealed a significant $120 million investment to enhance its API production capabilities in the U.S., bolstering drug supply resilience amidst growing demand.

Cambrex Announces $120 Million Investment in U.S. API Manufacturing to Ensure Drug Supply Resilience #USA #Cambrex #API_Manufacturing #Drug_Supply #Charles_City

Cambrex Announcements Major $120 Million Investment in API Manufacturing to Strengthen U.S. Drug Supply Cambrex announces a significant $120 million investment to enhance API manufacturing capabilities in the U.S., aiming to boost the local drug supply resilience.

Cambrex Announcements Major $120 Million Investment in API Manufacturing to Strengthen U.S. Drug Supply #United_States #Cambrex #API_Manufacturing #Drug_Supply #Charles_City